Phaseline

Targets › GLB1

GLB1 (Beta-galactosidase): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Metabolic and endocrine; next expected readout Feb 2028.

[Isoform 1]: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans..; FUNCTION: [Isoform 2]: Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the…. (UniProt, P16278)

Open in Phaseline: the race on GLB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gemma BiotherapeuticsPBGM01
AAVhu68 viral vector delivering functional GLB1 gene
GLB1Phase 1GM1 GangliosidosisFeb 2028
National Human Genome Research Institute (NHGRI)AAV9-GLB1
AAV9 vector expressing human beta-galactosidase (GLB1 gene product)
GLB1Phase 1Lysosomal DiseasesJan 2030

Conditions

GM1 Gangliosidosis (1) Lysosomal Diseases (1)

Modalities

protein or peptide (1), mixed (1)

Companies

Gemma Biotherapeutics (1) National Human Genome Research Institute (NHGRI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.